全文获取类型
收费全文 | 27976篇 |
免费 | 2616篇 |
国内免费 | 10篇 |
出版年
2022年 | 144篇 |
2021年 | 427篇 |
2020年 | 254篇 |
2019年 | 327篇 |
2018年 | 402篇 |
2017年 | 387篇 |
2016年 | 615篇 |
2015年 | 1052篇 |
2014年 | 1155篇 |
2013年 | 1464篇 |
2012年 | 1931篇 |
2011年 | 1990篇 |
2010年 | 1240篇 |
2009年 | 1056篇 |
2008年 | 1604篇 |
2007年 | 1683篇 |
2006年 | 1553篇 |
2005年 | 1551篇 |
2004年 | 1501篇 |
2003年 | 1388篇 |
2002年 | 1302篇 |
2001年 | 372篇 |
2000年 | 338篇 |
1999年 | 343篇 |
1998年 | 398篇 |
1997年 | 304篇 |
1996年 | 255篇 |
1995年 | 280篇 |
1994年 | 292篇 |
1993年 | 250篇 |
1992年 | 284篇 |
1991年 | 250篇 |
1990年 | 231篇 |
1989年 | 221篇 |
1988年 | 213篇 |
1987年 | 239篇 |
1986年 | 197篇 |
1985年 | 236篇 |
1984年 | 243篇 |
1983年 | 222篇 |
1982年 | 236篇 |
1981年 | 227篇 |
1980年 | 192篇 |
1979年 | 149篇 |
1978年 | 121篇 |
1977年 | 129篇 |
1976年 | 130篇 |
1975年 | 99篇 |
1974年 | 98篇 |
1973年 | 87篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
951.
Saghar Kaabinejadian Paolo A. Piazza Curtis P. McMurtrey Stephen R. Vernon Steven J. Cate Wilfried Bardet Fredda B. Schafer Kenneth W. Jackson Diana M. Campbell Rico Buchli Charles R. Rinaldo William H. Hildebrand 《PloS one》2013,8(6)
The recent West Nile virus (WNV) outbreak in the United States underscores the importance of understanding human immune responses to this pathogen. Via the presentation of viral peptide ligands at the cell surface, class I HLA mediate the T cell recognition and killing of WNV infected cells. At this time, there are two key unknowns in regards to understanding protective T cell immunity: 1) the number of viral ligands presented by the HLA of infected cells, and 2) the distribution of T cell responses to these available HLA/viral complexes. Here, comparative mass spectroscopy was applied to determine the number of WNV peptides presented by the HLA-A*11:01 of infected cells after which T cell responses to these HLA/WNV complexes were assessed. Six viral peptides derived from capsid, NS3, NS4b, and NS5 were presented. When T cells from infected individuals were tested for reactivity to these six viral ligands, polyfunctional T cells were focused on the GTL9 WNV capsid peptide, ligands from NS3, NS4b, and NS5 were less immunogenic, and two ligands were largely inert, demonstrating that class I HLA reduce the WNV polyprotein to a handful of immune targets and that polyfunctional T cells recognize infections by zeroing in on particular HLA/WNV epitopes. Such dominant HLA/peptide epitopes are poised to drive the development of WNV vaccines that elicit protective T cells as well as providing key antigens for immunoassays that establish correlates of viral immunity. 相似文献
952.
Xiaoning Han Michael Chen Fushun Wang Martha Windrem Su Wang Steven Shanz Qiwu Xu Nancy Ann Oberheim Lane Bekar Sarah Betstadt Alcino J. Silva Takahiro Takano Steven A. Goldman Maiken Nedergaard 《Cell Stem Cell》2013,12(3):342-353
Download : Download video (32MB) 相似文献
953.
Ruth Muchekehu Dingguo Liu Mark Horn Lioudmila Campbell Joselyn Del Rosario Michael Bacica Haim Moskowitz Trina Osothprarop Anouk Dirksen Venkata Doppalapudi Allan Kaspar Steven R. Pirie-Shepherd Julia Coronella 《Translational oncology》2013,6(5):562-IN6
Poor drug delivery and penetration of antibody-mediated therapies pose significant obstacles to effective treatment of solid tumors. This study explored the role of pharmacokinetics, valency, and molecular weight in maximizing drug delivery. Biodistribution of a fibroblast growth factor receptor 4 (FGFR4) targeting CovX-body (an FGFR4-binding peptide covalently linked to a nontargeting IgG scaffold; 150 kDa) and enzymatically generated FGFR4 targeting F(ab)2 (100 kDa) and Fab (50 kDa) fragments was measured. Peak tumor levels were achieved in 1 to 2 hours for Fab and F(ab)2versus 8 hours for IgG, and the percentage injected dose in tumors was 0.45%, 0.5%, and 2.5%, respectively, compared to 0.3%, 2%, and 6% of their nontargeting controls. To explore the contribution of multivalent binding, homodimeric peptides were conjugated to the different sized scaffolds, creating FGFR4 targeting IgG and F(ab)2 with four peptides and Fab with two peptides. Increased valency resulted in an increase in cell surface binding of the bivalent constructs. There was an inverse relationship between valency and intratumoral drug concentration, consistent with targeted consumption. Immunohistochemical analysis demonstrated increased size and increased cell binding decreased tumor penetration. The binding site barrier hypothesis suggests that limited tumor penetration, as a result of high-affinity binding, could result in decreased efficacy. In our studies, increased target binding translated into superior efficacy of the IgG instead, because of superior inhibition of FGFR4 proliferation pathways and dosing through the binding site barrier. Increasing valency is therefore an effective way to increase the efficacy of antibody-based drugs. 相似文献
954.
Nicholas D. Beyda Sloan Regen Russell E. Lewis Kevin W. Garey 《Current fungal infection reports》2013,7(2):119-125
Invasive Candida infections have increased fivefold over the past 20 years. During this time, the incidence of antifungal resistance and infection due to non-albicans species has risen with the increasing use of broad spectrum antifungals. As few new antifungal agents are in development, strategies to improve outcomes in the treatment of Candida infections are sorely needed. The use of immunotherapy to augment the host immune response as an adjunctive treatment for Candida infections is a potentially robust and promising approach. The purpose of this review is to focus on new developments in the use of adjunctive immunotherapy for the treatment of Candida infections, and discuss the potential impact of antifungal resistance on the host immune response. 相似文献
955.
Liang Cui Yie Hou Lee Yadunanda Kumar Fengguo Xu Kun Lu Eng Eong Ooi Steven R. Tannenbaum Choon Nam Ong 《PLoS neglected tropical diseases》2013,7(8)
Background
Dengue virus (DENV) is the most widespread arbovirus with an estimated 100 million infections occurring every year. Endemic in the tropical and subtropical areas of the world, dengue fever/dengue hemorrhagic fever (DF/DHF) is emerging as a major public health concern. The complex array of concurrent host physiologic changes has hampered a complete understanding of underlying molecular mechanisms of dengue pathogenesis.Methodology/Principle Findings
Systems level characterization of serum metabolome and lipidome of adult DF patients at early febrile, defervescence, and convalescent stages of DENV infection was performed using liquid chromatography- and gas chromatography-mass spectrometry. The tractability of following metabolite and lipid changes in a relatively large sample size (n = 44) across three prominent infection stages allowed the identification of critical physiologic changes that coincided with the different stages. Sixty differential metabolites were identified in our metabolomics analysis and the main metabolite classes were free fatty acids, acylcarnitines, phospholipids, and amino acids. Major perturbed metabolic pathways included fatty acid biosynthesis and β-oxidation, phospholipid catabolism, steroid hormone pathway, etc., suggesting the multifactorial nature of human host responses. Analysis of phospholipids and sphingolipids verified the temporal trends and revealed association with lymphocytes and platelets numbers. These metabolites were significantly perturbed during the early stages, and normalized to control levels at convalescent stage, suggesting their potential utility as prognostic markers.Conclusions/Significance
DENV infection causes temporally distinct serum metabolome and lipidome changes, and many of the differential metabolites are involved in acute inflammatory responses. Our global analyses revealed early anti-inflammatory responses working in concert to modulate early pro-inflammatory processes, thus preventing the host from development of pathologies by excessive or prolonged inflammation. This study is the first example of how an omic- approach can divulge the extensive, concurrent, and dynamic host responses elicited by DENV and offers plausible physiological insights to why DF is self limiting. 相似文献956.
Mazen Amatoury Vera Merheb Jessica Langer Xin Maggie Wang Russell Clive Dale Fabienne Brilot 《Journal of visualized experiments : JoVE》2013,(81)
Over the recent years, antibodies against surface and conformational proteins involved in neurotransmission have been detected in autoimmune CNS diseases in children and adults. These antibodies have been used to guide diagnosis and treatment. Cell-based assays have improved the detection of antibodies in patient serum. They are based on the surface expression of brain antigens on eukaryotic cells, which are then incubated with diluted patient sera followed by fluorochrome-conjugated secondary antibodies. After washing, secondary antibody binding is then analyzed by flow cytometry. Our group has developed a high-throughput flow cytometry live cell-based assay to reliably detect antibodies against specific neurotransmitter receptors. This flow cytometry method is straight forward, quantitative, efficient, and the use of a high-throughput sampler system allows for large patient cohorts to be easily assayed in a short space of time. Additionally, this cell-based assay can be easily adapted to detect antibodies to many different antigenic targets, both from the central nervous system and periphery. Discovering additional novel antibody biomarkers will enable prompt and accurate diagnosis and improve treatment of immune-mediated disorders. 相似文献
957.
Xiangdan Wang Valerie Quarmby Carl Ng Anan Chuntharapai Theresa Shek Charles Eigenbrot Robert F. Kelley Steven Shia Krista M McCutcheon John Lowe Cecilia Leddy Kyle Coachman Gary Cain Felix Chu Isidro Hotzel Mauricio Maia Eric Wakshull Jihong Yang 《MABS-AUSTIN》2013,5(4):540-554
Pharmacokinetic (PK) and immunohistochemistry (IHC) assays are essential to the evaluation of the safety and efficacy of therapeutic monoclonal antibodies (mAb) during drug development. These methods require reagents with a high degree of specificity because low concentrations of therapeutic antibody need to be detected in samples containing high concentrations of endogenous human immunoglobulins. Current assay reagent generation practices are labor-intensive and time-consuming. Moreover, these practices are molecule-specific and so only support one assay for one program at a time. Here, we describe a strategy to generate a unique assay reagent, 10C4, that preferentially recognizes a panel of recombinant human mAbs over endogenous human immunoglobulins. This “panel-specific” feature enables the reagent to be used in PK and IHC assays for multiple structurally-related therapeutic mAbs. Characterization revealed that the 10C4 epitope is conformational, extensive and mainly composed of non-CDR residues. Most key contact residues were conserved among structurally-related therapeutic mAbs, but the combination of these residues exists at low prevalence in endogenous human immunoglobulins. Interestingly, an indirect contact residue on the heavy chain of the therapeutic appears to play a critical role in determining whether or not it can bind to 10C4, but has no affect on target binding. This may allow us to improve the binding of therapeutic mAbs to 10C4 for assay development in the future. Here, for the first time, we present a strategy to develop a panel-specific reagent that can expedite the development of multiple clinical assays for structurally-related therapeutic mAbs. 相似文献
958.
Andrew Buchanan Veronica Clementel Rob Woods Nicholas Harn Michael A Bowen Wenjun Mo Bojana Popovic Steven M. Bishop William Dall’Acqua Ralph Minter Lutz Jermutus Vahe Bedian 《MABS-AUSTIN》2013,5(2):255-262
Antibodies can undergo a variety of covalent and non-covalent degradation reactions that have adverse effects on efficacy, safety, manufacture and storage. We had identified an antibody to Angiopoietin 2 (Ang2 mAb) that neutralizes Ang2 binding to its receptor in vitro and inhibits tumor growth in vivo. Despite favorable pharmacological activity, the Ang2 mAb preparations were heterogeneous, aggregated rapidly and were poorly expressed. Here, we report the engineering of the antibody variable and constant domains to generate an antibody with reduced propensity to aggregate, enhanced homogeneity, 11°C elevated Tm, 26-fold improved level of expression and retained activity. The engineered molecule, MEDI-3617, is now compatible with the large scale material supply required for clinical trials and is currently being evaluated in Phase 1 in cancer patients. This is the first report to describe the stability engineering of a therapeutic antibody addressing non canonical cysteine residues and the design strategy reported here is generally applicable to other therapeutic antibodies and proteins. 相似文献
959.
Eliane V. Wolf Annett Zei?ler Oliver Vosyka Evelyn Zeiler Stephan Sieber Steven H. L. Verhelst 《PloS one》2013,8(8)
Rhomboids are intramembrane serine proteases that play diverse biological roles, including some that are of potential therapeutical relevance. Up to date, rhomboid inhibitor assays are based on protein substrate cleavage. Although rhomboids have an overlapping substrate specificity, substrates cannot be used universally. To overcome the need for substrates, we developed a screening assay using fluorescence polarization activity-based protein profiling (FluoPol ABPP) that is compatible with membrane proteases. With FluoPol ABPP, we identified new inhibitors for the E. coli rhomboid GlpG. Among these was a structural class that has not yet been reported as rhomboid inhibitors: β-lactones. They form covalent and irreversible complexes with the active site serine of GlpG. The presence of alkyne handles on the β-lactones also allowed activity-based labeling. Overall, these molecules represent a new scaffold for future inhibitor and activity-based probe development, whereas the assay will allow inhibitor screening of ill-characterized membrane proteases. 相似文献
960.
Sarah Patterson Patricia Moran Elissa Epel Elizabeth Sinclair Margaret E. Kemeny Steven G. Deeks Peter Bacchetti Michael Acree Lorrie Epling Clemens Kirschbaum Frederick M. Hecht 《PloS one》2013,8(7)